Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Travanti Pharma, Inc.
WARNING LETTER
•Travanti Pharma, Inc.•February 28, 2008

Travanti Pharma, Inc. – FDA Warning Letter, Feb 28, 2008

Record Details

An FDA inspection conducted between February 19 and 28, 2008, at Travanti Pharma, Inc., identified significant violations in the conduct of clinical investigations for an investigational device-drug combination product. The inspection, part of the Bioresearch Monitoring Program, revealed the firm failed to adhere to applicable statutory requirements and FDA regulations. Key deficiencies included the failure to submit an Investigational New Drug (IND) application for studies subject to 21 CFR 312.2(a), 312.20(a), and 312.40(a). Additionally, Travanti Pharma failed to obtain investigator statements (Form FDA 1572) as required by 21 CFR 312.53(c)(1), did not select a qualified monitor for the investigations (21 CFR 312.53(d)), and failed to maintain adequate records for investigational drug disposition (CFR 312.57(a)). The firm also neglected to maintain complete and accurate records of investigators' financial interests under 21 CFR Part 54, as described in 21 CFR 312.57(b). While Travanti Pharma acknowledged the IND requirement and committed to future compliance, their response lacked detailed corrective action plans. The FDA requires a written response within fifteen working days outlining specific actions, including corrective action plans and SOPs, to prevent recurrence. Failure to adequately address these violations may lead to further regulatory action.

Company
Travanti Pharma, Inc.
Inspection date
February 28, 2008
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Leslie K. Ball
  • Constance Lewin
View Company Profile

ID · 5a85e7f6-3de3-4804-a454-8f8e49f5c39c

Violation Codes9
21 CFR 312.2(a)21 CFR 312.20(a)21 CFR 312.40(a)21 CFR 312.53(c)(1)21 CFR 312.53(d)21 CFR 312.57(a)21 CFR 312.57(b)21 CFR 54(a)(3)(i)21 CFR 54(a)(3)(iii)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Travanti Pharma, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.